ABSTRACT
Heart failure is a complex syndrome that contributes significantly to mortality and morbidity in the Unites States. Self-management is an ACC/AHA-recommended management tool for chronic conditions, however, those with congestive heart failure have historically poor compliance, low health literacy, and comorbidities that lead to reduced adherence to therapies and lifestyle modifications. Digital health technologies have the potential to enhance care and improve self-management. This manuscript describes the rationale and challenges of the design and implementation of a pragmatic randomized controlled trial to evaluate the efficacy of three digital health technologies in the management of congestive heart failure. Leveraging the use of a fully electronic enrollment and consent platform, the trial will randomize 200 patients across heart failure clinics in the Yale New Haven Health system to receive either usual care or one of three distinct digital technologies designed to promote self-management and provide critical data to clinicians. Our primary outcome will measure the change in quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) at 3 months. Initial recruitment efforts have highlighted the large digital divide in our population of interest. Assessing not only clinical outcomes, but patient usability and ease of clinical integration of digital technologies will prove beneficial in determining the feasibility and success of the integration of such technologies into the healthcare system. Future learnings will illustrate strategies to improve patient engagement with, and integration of, digital health technologies to enhance the patient-clinician relationship.
Clinicaltrials.gov NCT04394754
Competing Interest Statement
This study is funded by Boehringer Ingelheim. However, the authors have full jurisdiction over all aspects of study design, conduct, analysis and publication. Dr. Wilson is Founder of Efference, LLC, a medical communications company. Receives support from NIH R01DK113191, R01HS027626, P30DK079310. Dr. Desai is under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures used for public reporting and pay for performance programs. Reports research grants and consulting for Amgen, Astra Zeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Relypsa, Novartis, and SCPharmaceuticals.
Clinical Trial
NCT04394754
Funding Statement
This study is funded by Boehringer Ingelheim. However, the authors have full jurisdiction over all aspects of study design, conduct, analysis and publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial is conducted under approval of the Yale University Institutional Review Board and adheres to the principles of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declaration of interests: This study is funded by Boehringer Ingelheim. However, the authors have full jurisdiction over all aspects of study design, conduct, analysis, and publication.
FPW: Founder of Efference, LLC, a medical communications company. Receives support from NIH R01DK113191, R01HS027626, P30DK079310
NRD: Under contract with the Centers for Medicare and Medicaid Services to develop and maintain performance measures used for public reporting and pay for performance programs. Reports research grants and consulting for Amgen, Astra Zeneca, Boehringer Ingelheim, Cytokinetics, MyoKardia, Relypsa, Novartis, and SCPharmaceuticals.
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- HF
- heart failure
- HFrEF
- heart failure with reduced ejection fraction
- HFpEF
- heart failure with preserved ejection fraction
- CHF
- congestive heart failure
- KCCQ
- Kansas City Cardiomyopathy Questionnaire
